PDCD1 and neoplasm: Moreover, adaptive upregulation of LAG-3 expression may result in treatment resistance and tumor progression in patients receiving anti-PD-1 therapy, and anti-LAG-3 in combination with nivolumab could potentially restore T cell activation and tumor response.